



REVIEW

Effect of exercise on cognitive function in chronic disease patients: a meta-analysis and systematic review of randomized controlled trials

Hong Cai* Guichen Li* Shanshan Hua Yufei Liu Li Chen

School of Nursing, Jilin University, Changchun, Jilin, People's Republic of China

*These authors contributed equally to this work

Background: The purpose of this study was to conduct a meta-analysis and systematic review to assess the effect of exercise on cognitive function in people with chronic diseases.

Methods: PubMed, Web of Science, Embase, the Cochrane Library, CINAHL, PsycINFO, and three Chinese databases were electronically searched for papers that were published until September 2016. This meta-analysis and systematic review included randomized controlled trials that evaluated the effect of exercise on cognitive function compared with control group for people with chronic diseases.

Results: Totally, 35 studies met the inclusion criteria, with 3,113 participants. The main analysis revealed a positive overall random effect of exercise intervention on cognitive function in patients with chronic diseases. The secondary analysis revealed that aerobic exercise interventions and aerobic included exercise interventions had a positive effect on cognition in patients with chronic diseases. The intervention offering low frequency had a positive effect on cognitive function in patients with chronic diseases. Finally, we found that interventions offered at both low exercise intensity and moderate exercise intensity had a positive effect on cognitive function in patients with chronic diseases. The secondary analysis also revealed that exercise interventions were beneficial in Alzheimer's disease patients when grouped by disease type.

Conclusion: This meta-analysis and systematic review suggests that exercise interventions positively influence cognitive function in patients with chronic diseases. Beneficial effect was independent of the type of disease, type of exercise, frequency, and the intensity of the exercise

Keywords: exercise, cognitive function, physical activity

Abbreviations

ACE-R, Addenbrooke's Cognitive Examination-Revised; ADAS-Cog, Alzheimer's Disease Assessment Scale-cognitive subscale; AIDS, acquired immune deficiency syndrome; BCPT-cog, Breast Cancer Prevention Trial symptom checklist-cognitive problems scale; BDI-cog, Beck Depression Inventory-cognitive subscale; BDNF, brain-derived neurotrophic factor; BOPI-cog, Breast Cancer Prevention Trial Symptom Checklist-Cognitive Problems Scale; CDT, clock drawing test; CI, confidence interval; CINAHL, Cumulative Index to Nursing and Health Literature; CNKI, China National Knowledge Infrastructure; EORTC-cog, European Organization for Research and Treatment of Cancer-cognitive; ERFC, Rapid Evaluation of Cognitive Function; FAB, Frontal Assessment Battery; FACS, functional assessment of communication skills; HR_{max} , maximum heart rate; MCI, mild cognitive impairment; IL, interleukin; MD, mean difference; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive

Correspondence: Li Chen School of Nursing, Jilin University, No 965 Xinjiang Street, Changchun, Jilin 130021, People's Republic of China Tel/fax +86 431 8561 9366 Email chen care@126.com

Assessment; PFS-cog, Piper Fatigue Scale-cognitive; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; SLCT, six-letter cancellation test; SMD, standardized mean difference; TCD, total cognitive domain; TNF-α, tumor necrosis factor-alpha.

Introduction

Chronic diseases are long-term conditions with slow disease progression and without an effective cure,1 and 38 million people die from chronic diseases each year. In addition, 16 million of these deaths occur before the age of 70 years. Chronic diseases may lead to alteration in brain structure and function and are associated with cognitive change.²⁻⁵ Some of these changes may be related to neurodegenerative diseases (such as Alzheimer's disease and other types of dementia), increased dementia incidence, and cognitive decline. Strategies are needed to reduce disease-related cognitive impairment in chronic disease patients.

Exercise, the aim of which is to improve or maintain physical fitness, is a subset of physical activity that is planned, structured, and flexible, in addition to promoting aerobic endurance. Exercise is essential in maintaining physical function and physiological health. The results of animal studies have identified that engagement in physical activity may enhance neurotrophic factor levels, 7,8 neurogenesis, 9,10 and vascularization¹¹ and may even reduce aggregation of pathogenic proteins, 12,13 mediate neuroinflammation, 13 and inhibit neuronal dysfunction.¹⁴ Exercise also appears to be associated with the maintenance of brain health and cognitive performance in cognitively normal older adults. Most experimental studies have identified increased lifetime physical activity to be associated with reduced risk of suffering from dementia in cognitively normal older persons. 15-17 The results of a meta-analysis of prospective studies on physical activity and the risk of cognitive decline, which included 15 prospective studies (12 cohorts) with 33,816 nondemented subjects followed for 1-12 years, showed that a total of 3,210 patients demonstrated cognitive decline during the follow-up period. The results of the cumulative analysis indicated that subjects who performed high levels of physical activity were significantly less likely to demonstrate cognitive decline during the follow-up period.18

The results of a meta-analysis of the effect of physical activity on cognitive function in patients with dementia suggested that physical activity interventions positively influenced cognitive function in patients with dementia.¹⁹ The results of another meta-analysis of aerobic exercise implied that this practice promotes cognitive function in older adults

with mild cognitive impairment, finding that aerobic exercise was associated with an improvement in global cognitive ability.²⁰ However, a comprehensive evaluation of the effect of exercise interventions on cognitive function in chronic disease patients has not been conducted. We therefore conducted a meta-analysis and systematic review of randomized controlled trials investigating the effect of exercise intervention on cognitive outcomes in chronic disease patients.

Methods

Protocol and registration

The meta-analysis was conducted and reported in accordance with the PRISMA guidelines²¹ to ensure comprehensive and transparent reporting of our methods and results.

Search strategy

PubMed, Web of Science, Embase, the Cochrane Library, CINAHL, PsycINFO, and three Chinese databases (CNKI, WanFang Data, and VIP) were electronically searched for papers that were published until September 2016. The search strategy included various combinations of the terms "Cognition", "Cognitive function", and "MMSE", with exercise intervention terms such as "Exercise" or "Muscle Stretching Exercises" or "Resistance Training" or "Running" or "Swimming" or "Walking" or "Cycling" or "Physical activity" or "Aerobic" or "Yoga" or "Tai Chi" or "Qigong". Randomized controlled trials were specifically targeted using the following search terms: "Randomized controlled trial", "Controlled clinical trial", or "Randomized" or "Randomly" or "Trial" or "Group". The search was limited to human studies.

Eligibility criteria

Types of studies

Only randomized controlled trials were included in this review. No publication date restrictions were imposed on the initial search.

Types of participants

The participants were adults (≥18 years) who had been diagnosed with a chronic disease (eg, arthritis, asthma, cancer, COPD, diabetes, heart disease, or AIDS). Participants with mental problems were excluded.

Types of interventions

The inclusion criteria were as follows: 1) the intervention group underwent exercise intervention. When a study included two or more intervention groups that were found to be eligible criteria, we included all in the meta-analysis; 2) the control

group did not undergo any type of exercise intervention. However, studies in which exercise training was part of an intervention with multiple components (eg, combined with a drug intervention) were excluded.

Types of outcomes

The studies were required to report global cognitive function as the outcome measure. Any studies reporting only the results for a specific cognition scale, including scales assessing memory, attention, language, verbal fluency, visuospatial ability, or executive ability, were excluded.

Study selection

The study selection process is outlined in Figure 1. The eligibility assessment was performed by two independent reviewers in a standardized manner. All papers identified using the search strategy were assessed for eligibility, as indicated based on the previously defined inclusion criteria, by reviewing their titles and/or abstracts. If insufficient information was available to evaluate the inclusion or exclusion of an article, then a full-text version was obtained. Full-text versions of all the relevant studies were obtained and reviewed by two independent reviewers to ensure that the studies met the inclusion criteria. Disagreements were resolved by discussion with a third reviewer. When insufficient information or data were available in the included articles, the authors were contacted to obtain additional information if possible.

Quality assessment

Two reviewers independently assessed the quality of all included studies, using the Downs and Black Quality Index. The scales are designed to assess the methodological quality of randomized studies of health care interventions²² and include reporting, external validity, bias, confounding, and

power, and their maximum scores are 11, 3, 7, 6, and 5, respectively. The maximum possible total score is 32. Quality was then rated on a four-category scale: poor (<18), moderate (18–23), good (24–29), and excellent (\ge 30).

Data extraction and statistical analysis

Data were extracted from the included articles using a data extraction form (Table 1). Sample characteristics were collected, including the sample size, intervention and control group sizes, diagnoses, baseline MMSE scores, and age. Details on exercise interventions were collected, including intervention category, frequency, duration, HR_{max}, and exercise intensity. The effects of the exercise training interventions, including cognitive function measures and the study results, were extracted. One investigator performed the data extraction, which was checked by a second investigator.

The statistical analyses were performed using version 5.3 of the RevMan meta-analysis software. The intervention effect sizes for continuous variables were measured by determining the SMDs between the intervention and control groups with regard to the change observed between the baseline and follow-up cognitive scores and their corresponding 95% CI. According to the recommendations of the Cochrane Handbook for Systematic Reviews of Interventions, published by Cochrane Collaboration and Wiley, the selection of fixed- or random-effects model is based on the underlying effect of the intervention.²³ Due to the expected heterogeneity across studies (eg, different intervention types and cognitive outcome measurements), we performed random-effects meta-analysis. Additionally, when the heterogeneity identified across studies was high, a subgroup analysis was performed to identify potential causes of heterogeneity, including exercise types, types of disease, exercise frequency, and intensity. Heterogeneity




Figure I Flow diagram of literature search.

Table I Patient characteristics of included studies

(γεαλ) Τ call Intervention) Diggrough Baseline Age, Intervention Intervention (2012) Accorded (2013) T call Intervention Diggrough HVFSE years Accorded (2013) T call Intervention Diggrough HVFSE years Accorded (2013) T call Intervention Diggrough T call (2013) T c	First author	Samp	Sample characteristics	ics			Intervention characteristics	characteristic	SS			Outcome	
Mathematic National Programs Mathematic National Programs Mathematic National	(year)	Total	1			Age,	Intervention	Frequency,	Duration,		Exercise	Selected cognitive	Conclusion
1374 20 101/10 Altheimer's disease 21.15 78.75 Aerobic 60 10 10 10 10 10 10 10		z	control, n	1		years	category	min/wk	weeks	S	intensity	measurement	
81 44472 Cancer Uhilcrown 6.2 Aerobic 610 10 Unknown Low Moderate 52 28272 Oxnoo Cancer 116 36 Aerobic 610 135–180 10 Unknown Low FORT-Cog 40 20.00 Cancer 146 Resistance 135–180 19 70%-60% High ACER 20 1 (101) Cancer Uhinorom 20.7 18 40% Low MYRE 21 1 (115) MCI 21.29 77.9 Aerobic 90 12 Unknown MYRE 21 1 (115) MCI 21.29 77.9 Aerobic 90 12 Unknown MYRE 21 1 (117) MCI 1.0 MYRE Andrew MYRE ACER 21 1 (117) MYRE 1.0 MYRE MYRE ACER MYRE 22 1 (117) MYRE 2.0 MYRE MYRE ACER ACER AC	Arcoverde (2013) ²⁴	20	01/01	Alzheimer's disease	21.15	78.75	Aerobic	09	12	%09	Moderate	MMSE	Yes
51 SEAD Conscordativitie free 23.4 78.9 Aerobic 60-12.0 20 Unknown Low MPRE 200 100/10 Strocke 13.4 78.9 4evobic 90 12 0.04/sown Low MPRE 200 100/10 Cancer 1.04/sown 1.6 Aerobic 90 1.2 60% Moderate NPINE 10 1.511.5 MCC 1.04/sown 1.0 1.0 40% Moderate NPINE 1 1.6 1.6 1.0 1.0 1.0 40% Moderate NPINE 1 1.6 1.0 1.0 1.0 1.0 1.0 Moderate NPINE 1 1.6 1.0 1.0 1.0 1.0 1.0 Moderate NPINE 1 1.0 1.0 1.0 1.0 1.0 1.0 Moderate NPINE 1 1.0 1.0 1.0 1.0 1.0	Oh (2012) ⁴²	8	44/37	Cancer		62	Aerobic	180	01	Unknown	Low	EORTC-cog	Yes
40 2020 Stroke 8.8 6.9 Resistance 13-180 19 70%-80% High ACER 20 17/15 MCI 20.7 8.1 6.9 12 Unknown Low MYSE 21 17/15 MCI 20.7 7.3 Acrobic 90 12 Unknown Low MYSE 20 17/15 MCI 20.7 7.3 Acrobic 90 12 Unknown Low MYSE 20 17/15 MCI 20.7 7.3 Acrobic 90 12 Unknown Low MYSE 20 17/15 MCI Unknown 1.0 1.0 1.0 MYSE PRACC 20 18/17 Held Chror Unknown 1.0 MYSE PRACC 1.0 MYSE 20 18/17 Held MYSE	Tsai (2013) ⁴⁴	22	28/27	Osteoarthritic knee	25.45	78.91	Aerobic	60-120	20	Unknown	Low	MMSE	°N
200 100/100 Carcer Uhlrown 13 A erobic 90 12 Uhlrown Low PRCPT-CPS 90 15/15 MCI 20.77 73 A erobic 90 12 40% Moderate MYSE 91 15/15 MCI 21.29 77.9 A erobic 90 12 40% Moderate MYSE 91 168 47/121 Heart failure Uhlrown 10 10 10 10 MYSE MYSE 91 88 44/44 Carcer Uhlrown 12.75 Aerobic 90 12 60% MYSE MYSE 91 98 47/121 Heart failure Uhlrown 12.75 Aerobic 90 12 60% MYSE MYSE 10 17/10 Athriemer's disease 18 7.3 Combined 10 9 10 MYSE MYSE 10 17/10 Athriemer's disease 18 7.3	Moore (2015) ⁴¹	40	20/20	Stroke		69	Resistance	135-180	61	20%—80%	High	ACE-R	Yes
31 17/15 MCL 12.97 78.3 Aerobic 90 12 40% Low MMSE 9.1 51.5 MCL 12.97 78.4 Aerobic 90 12 40% Low MMSE 9.1 51.2 56.7 MCL 21.2 7.4 Aerobic 180 12 40% Low MMSE 9.1 51.2 56.7 MCL 21.2 7.4 Aerobic 180 12 40% MCGerate ADAS-cog 9.1 18.1 1.5 MCC Unknown 1.2 40% MCGerate CORT 9.1 1.5 1.6 MCC MCC MCC MCC MCC 9.1 1.5 1.6 MCC MCC MCC MCC MCC MCC 1.0 1.6 MCC	Derry (2015) ²⁹	200	100/100	Cancer	-	51.6	Aerobic	90	12	Unknown	Low	BCPT-CPS	Yes
11 (1) (1) (1) (1) (1) (1) (1) (1) (1) (Varela (2011) ⁵¹	32	17/15	MCI	20.77	78.3	Aerobic	90	12	40%	Low	MMSE	°Z
11 53 2.6.77 MCI Acrobic 180 18 50%-60% Indeparte ADD-Scog 8 4.4.44 Cancer Unknown 68.9 Aerobic 180 12 Unknown LONG-Cog 8 4.4.44 Cancer Unknown 4.5.3 Aerobic 180 6 Unknown LONG-Cog 1.1 15/16 Fibrounyligha Unknown 1.2.3 Aerobic 2.0 Unknown LONG-Cog 1.4 70/70 Alzheimer's disase 1.7.7 7.7.3 Combined 1.0 Unknown Post Unknown Post CDT 1.4 70/70 Alzheimer's disase 1.2.7 7.7.3 Combined 1.0 Unknown Moderate EDR-Cog 1.4 70/70 Alzheimer's disase 1.2.7 Azio Moderate CDT 1.4 70/70 Alzheimer's disase 1.2.7 Azio Moderate CDT 1.4 70/70 Alzheimer's disases <	Varela (2011) ⁵¹	30	15/15	MCI	21.29	77.9	Aerobic	90	12	%09	Moderate	MMSE	°Z
0 168 47/121 Unknown 68.9 Aerobic 180 12 Unknown MYGE 4 4 Cancer Unknown 47.5 Aerobic 180 12 Unknown High EORTC-cog 3 13.16 Fibromyaliga Unknown 47.5 Aerobic 10 12 Unknown 180 EORTC-cog 3 18/16 Fibromyaliga Unknown 47.9 Aerobic 10 5 Unknown Low EORTC-cog 3 18/16 Alzheimer's disease 17.7 77.9 Combined 12 Onknown Low CDT 3 18/17 Arabeimer's disease 17.7 77.2 Combined 12 Onknown Low CDT 3 18/17 Arabeimer's disease 18.7	Hildreth (2015) ³³	53	26/27	MCI		64.5	Aerobic	180	<u>8</u>	%09%09	Moderate	ADAS-cog	°Z
9 84 444 Cancer Uhknown 475 Aerobic 180 6 Uhknown Low EORTC-cog 1 1 516 Flbromyalga Uhknown 475 Aerobic 19 23 60%-75% Moderate EORTC-cog 1 1 516 Flbromyalga Uhknown 475 Aerobic 210 6 Uhknown How EORTC-cog 1 1 5070 Aktheimer's disease 1877 Combined 120 6 Uhknown How CDT 2 1 40 7070 Aktheimer's disease 1877 Combined 120 6 Uhknown How CDT 2 1 40 7070 Aktheimer's disease 18.7 Aerobic 10 6 Uhknown How CDT 2 1 40 7070 Aktheimer's disease 18.7 Aerobic 10 6 Uhknown How CDT 2 1 40 17.2 Aktheimer's disease 18.7 Aerobic 10 6 Uhknown How CDT 2 1 59/61	Lindsay (2014) ⁴⁰	891	47/121	Heart failure		86.89	Aerobic	180	12	Unknown	Moderate	MMSE	Š
4 98 49/49 Cancer Uhknown 327 Resistance 12 Uhknown High EORTC-cog 1 15/16 Fibromysiga Unknown 439 400,473 Moderate BDL-cog 1 15/16 Fibromysiga Unknown 439 Archine 120 48 Unknown Low 1 140 70/70 Alzheimer's disease 17.5 73 Combined 120 48 Unknown Low CDT 2008) ¹⁴ 19 Alzheimer's disease 18.7 72.0 Ambring 17.0 Alzheimer's disease 18.7 7.0 Ambring CDT 2008) ¹⁴ 19 Alzheimer's disease 18.7 Azerobic 19 10.0	Vadiraja (2009) ⁴⁹	88	44/44	Cancer	Unknown	47.5	Aerobic	180	9	Unknown	Low	EORTC-cog	Yes
1 15 6 Fibromyalgia Uhknown 1358 Aerobic 210 6 0 Uhknown Low PFS-cog 1 10 20/70 Azheimer's disease 17.7 77.9 Combined 120 6 0 Uhknown Low PFS-cog 1 20 20/70 Azheimer's disease 18.1 78.2 Combined 120 6 0 Uhknown Low PFS-cog 2 39/81 Climateric syndrome Uhknown Low Moderate CDT 3 4 39/35 Azheimer's disease 18.7 81.3 Aerobic 19.0 8 Uhknown Low PMSE 5 30/26 Azheimer's disease 18.7 81.3 Aerobic 19.0 12 Uhknown Low PMSE 5 30/26 Azheimer's disease 18.7 81.3 Aerobic 19.0 12 Uhknown Low PMSE 5 30/26 Azheimer's disease 18.7 81.3 Aerobic 19.0 12 Uhknown Low PMSE 5 30/26 Azheimer's disease 28.7 Aerobic 19.0 12 Uhknown Low PMSE 5 30/26 Azheimer's disease 28.7 Aerobic 19.0 12 Solf-70% Moderate FAB 6 4 21/13 MCI Azheimer's disease 28.7 Aerobic 19.0 12 Solf-70% Moderate FAB 7 4 39/35 Azheimer's disease 28.7 Aerobic 19.0 12 Solf-70% Moderate FAB 8 4 21/13 MCI Azheimer's disease 28.7 Aerobic 19.0 12 Solf-70% Moderate ADAS-cog 8 4 21/13 MCI Azheimer's disease 18.0 18.	Schmidt (2015) ⁴⁵	86	49/49	Cancer	Unknown	52.7	Resistance	120	12	Unknown	High	EORTC-cog	°N
35 181/17 Cancer Unknown 13.58 Aerobic 210 6 Unknown Low PFS-cog 14 70/70 Alzheimer's disease 11.75 7.79 Combined 120 48 Unknown Low CDT 25 180 Alzheimer's disease 18.1 78.2 Combined 120 48 Unknown Low CDT 2008)*** 10 27/61 Alzheimer's disease 18.1 78.2 Combined 120 48 Unknown CDT 2008)*** 10 27/61 Archoire 10 90 Unknown Low CDT 2008)*** 17.20 Alzheimer's disease 13.7 Aerobic 190 1 Unknown Moderate CDT 153** 40 21/19 Parkinson's disease 18.1 Aerobic 19 1 Unknown Moderate ADAS-cog 153** 40 21/19 Parkinson's disease 18.4 Arcobic	Gowans (2001) ³¹	3.	15/16	Fibromyalgia	-	47.94	Aerobic	90	23	60%-75%	Moderate	BDI-cog	Yes
1 40 70/70 Albeimer's disease 17.75 7.79 Combined 120 48 Unknown Low CDT 2.5 140 70/70 Alzheimer's disease 15.0 2.0 Combined 120 48 Unknown Moderate CDT 2.5 120 59/61 Climacteric syndrome Unknown 48.5 Aerobic 300 8 Unknown Moderate CDT 2.08 3 3/35 Alzheimer's disease 18.7 76.7 Resistance 180 12 Unknown Low MYSE 2.08 3 0/22 Alzheimer's disease 18.7 Aerobic 180 12 Unknown Low MYSE 2.08 1 1/12 Alzheimer's disease 2.8.7 Aerobic 80 12 Unknown Moderate ACC 153.7 2.7 Azheimer's disease 2.8.7 Aerobic 80 12 Unknown Moderate ACC 153.7 2.7 Arbeimer's disease	Kim (2005) ³⁵	35	18/17	Cancer		33.58	Aerobic	210	9	Unknown	Low	PFS-cog	Yes
140 7070	Ohman (2016) ⁴³	140	70/70	Alzheimer's disease	17.75	77.9	Combined	120	48	Unknown	Low	CDT	Ŷ
33 189 73/116 Alzheimer's disease 15.03 8.20.2 Aerobic 105 60 Unknown Low MMSE 2008/4 3 (1) Gilmaceric sordrome 11,000 41.0 Unknown Low 17.0 MMSE 2008/4 3 (1) Alzheimer's disease 13.7 76.7 Resistance 180 12 Unknown Low MMSE 2008/4/3 30 17/20 Alzheimer's disease 28.2 Aerobic 60 12 Unknown Low FAB 15) ²³ / ₂ 30 17/20 Alzheimer's disease 28.2 Aerobic 60 12 Unknown FAB 15) ²³ / ₄ 40 11/19 Parkinson's disease 28.4 Aerobic 80 12 Unknown FAB 15) ²³ / ₄ 40 11/19 Parkinson's disease 28.4 Aerobic 80 12 Unknown Moderate FAB 2,1 17/18 MCI Alzheimer's disease 28.4 <td>Ohman (2016)⁴³</td> <td>140</td> <td>70/70</td> <td>Alzheimer's disease</td> <td>1.81</td> <td>78.2</td> <td>Combined</td> <td>120</td> <td>48</td> <td>Unknown</td> <td>Moderate</td> <td>CDT</td> <td>°N</td>	Ohman (2016) ⁴³	140	70/70	Alzheimer's disease	1.81	78.2	Combined	120	48	Unknown	Moderate	CDT	°N
2008/44 120 59/61 Climacteric syndrome Unknown Low SICT 2008/44 30 Alzheimer's disease 13.7 6.7 Resistance 180 12 Unknown Low MMSE 2008/44 30 Alzheimer's disease 13.7 6.7 Resistance 180 12 Unknown Low MMSE 15)32 30/26 Alzheimer's disease 2.8.4 Aerobic 10 10 Unknown Moderate FAG 15)32 30 15/15 Alzheimer's disease 2.8.4 Combined 90 12 50%-70% Moderate FAB 20 15/12 Alzheimer's disease 2.8.4 Acrobic 180 48 Unknown Moderate FAB 20 15/12 Alzheimer's disease 1.8.7 7.8.4 Aerobic 180 48 Unknown Moderate FAB 20 15/13 MCI 2.6.4 7.8.4 Aerobic 180 1.2 Un	Cancela (2016) ²⁵	189	73/116	Alzheimer's disease		82.02	Aerobic	105	09	Unknown	Low	MMSE	Yes
74 39,35 Alzheimer's disease 18.7 81.38 Aerobic 180 12 Unknown Low MMSE 2008** 30 Alzheimer's disease 18.7 74.7 Resistance 180 24 Unknown Noderate PACS 15)3* 30 Alzheimer's disease 28.25 68.77 Aerobic 60 12 50%-70% Moderate FAB 15)3* 40 21/19 Parkinson's disease 28.41 65.86 Resistance 60 12 50%-70% Moderate FAB 15)3* 40 21/19 Parkinson's disease 28.41 65.86 Resistance 60 12 50%-70% Moderate FAB 24 17/11 MCI 27.5 Aerobic 90 12 Unknown ADAS-cog 25 17/12 MCI 10known 65.7 Aerobic 12 Unknown Moderate ADAS-cog 26 17/12 MCI MCI 27	Chattha (2008) ²⁶	120	19/65	Climacteric syndrome	Unknown	48.5	Aerobic	300	8	Unknown	Low	SLCT	Yes
2008) ³⁴ 30 1720 Alzheimer's disease 13.7 76.7 Resistance 180 24 Unknown Moderate MMSE FACS 30.76 Alzheimer's disease 2.8 8.2 Aerobic 15.0 12 50%–70% Moderate FAB FACS 15.1 17.1 McImor's disease 2.8.4 6.8 Resistance 6.0 12 50%–70% Moderate FAB FAB FACS 15.1 17.1 McImor's disease 2.8.4 6.8 Resistance 6.0 12 50%–70% Moderate FAB FAB FAITH MCImor's disease 2.0.7 7.2 Aerobic 180 48 Unknown Moderate MMSE 17.1 McImor's disease 18.5 7.5 75.4 Aerobic 180 48 Unknown Moderate MMSE 17.1 McImor's disease 18.5 7.5 75.4 Aerobic 180 12 Unknown Moderate ADAS-cog 18.5 36.49 Alzheimer's disease 18.9 7.6.6 Aerobic 180 12 Unknown Moderate MMSE 18.5 36.49 Alzheimer's disease 18.9 7.6.6 Aerobic 180 12 Unknown Moderate MMSE 19.1 MCImor	Cheng $(2014)^{27}$	74	39/35	Alzheimer's disease	6	81.38	Aerobic	180	12	Unknown	Low	MMSE	Yes
56 30/26 Alzheimer's disease 58 8.2.5 Aerobic 150 16 Unkrown Low FACS 15)32 38 1919 Parkinson's disease 28.25 8.8.77 Aerobic 60 12 50%-70% Moderate FAB 15)32 30 15/15 Parkinson's disease 28.41 Aerobic 60 12 50%-70% Moderate FAB 15/3 147/131 MCI 24.5 7.24 Combined 90 12 Unknown Moderate FAB 2011)34 170 85/85 MCI 1.78.2 Aerobic 180 12 Unknown Moderate ADAS-cog 2011)34 170 85/85 MCI Unknown 86.5 Genbined 180 12 Unknown MOderate ADAS-cog 2011 MCI Alzheimer's disease 1.80 1.6 1.0 Unknown Moderate ADAS-cog 2014 Ag/9 Alzheimer's disease	Christofoletti (2008) ⁵⁴	30	17/20	Alzheimer's disease	13.7	7.97	Resistance	180	24	Unknown	Moderate	MMSE	°N
15) ³² 38 19/19 Parkinson's disease 28.25 68.77 Aerobic 60 12 50%-70% 50%-70% Moderate FAB 15) ³² 40 21/19 Parkinson's disease 28.41 65.86 Resistance 60 12 50%-70% 50%-70% Moderate FAB 24 15/11 Alzheimer's disease 28.41 65.86 Resistance 60 12 10known Moderate FAB 278 147/13 MCI 24.5 75.45 Aerobic 90 48 Unknown ADAS-cog 2011) ³⁸ 170 85/85 MCI Unknown 68.65 Combined 150 24 Unknown ADAS-cog 140 23/23 MCI Unknown 68.65 Combined 150 Unknown Moderate ADAS-cog 140 23/23 MCI Unknown 67.7 Aerobic 180 15 Unknown Moderate ADAS-cog 149 20/17 <td< td=""><td>Cott $(2002)^{28}$</td><td>26</td><td>30/26</td><td>Alzheimer's disease</td><td></td><td>82.5</td><td>Aerobic</td><td>150</td><td>91</td><td>Unknown</td><td>Low</td><td>FACS</td><td>N_o</td></td<>	Cott $(2002)^{28}$	26	30/26	Alzheimer's disease		82.5	Aerobic	150	91	Unknown	Low	FACS	N _o
5)	Hashimoto (2015) ³²	38	61/61	Parkinson's disease		68.77	Aerobic	09	12	20%-70%	Moderate	FAB	Yes
15/15 15/15 Alzheimer's disease 20.6 72.4 Combined 90 12 Unknown Moderate MMSE 17/12 MCI 24.5 77.84 Aerobic 180 48 Unknown Low MMSE 17/12 MCI 24.5 77.82 Aerobic 180 48 Unknown Moderate ADAS-cog 18.5 36.49 Alzheimer's disease 18.9 76.66 Aerobic 180 12 Unknown Moderate ADAS-cog 18.5 36.49 Alzheimer's disease 14.0 81.0 Combined 40 48 40%-60% Moderate MMSE 19.1 20/17 MCI Molemer's disease 14.0 81.0 Combined 40 48 40%-60% Moderate MMSE 19.1 20/15 McI Alzheimer's disease Unknown 81.65 Combined 180 12 Unknown Moderate MMSE 19.1 26/25 MCI Alzheimer's disease Unknown 81.65 Combined 180 120 Unknown Moderate MMSE 19.1 20/20 Alzheimer's disease Unknown 81.65 Combined 180 120 Unknown Moderate MMSE 19.1 20/20 Alzheimer's disease Unknown 81.65 Combined 210 17.3 Unknown Moderate MMSE 19.1 20/20 Alzheimer's disease 22.00 74.1 Combined 210 17.3 Unknown Moderate MMSE 19.1 20/20 Alzheimer's disease 22.00 74.1 Combined 210 17.3 Unknown Moderate MMSE 19.1 20/20 MCI 20/20 Alzheimer's disease 22.00 24.67 66 Aerobic 120 24.67 66 Aerobic 24.67 24.6	Hashimoto (2015) ³²	40	21/19	Parkinson's disease	28.41	98.59	Resistance	09	12	20%-70%	Moderate	FAB	Yes
251 147/131 MCI 25.7 75.45 Aerobic 180 48 Unknown Low MMSE 261 171/218 MCI 24.5 77.82 Aerobic 90 48 Unknown Low MMSE 46 171/218 MCI Unknown 68.65 Combined 150 24 Unknown Moderate ADAS-cog 46 23/23 MCI Loke Aerobic 12 Unknown Moderate ADAS-cog 114}s 37 20/17 MCI Alzheimer's disease 1.8 7.6.6 Aerobic 180 15 Unknown Moderate ADAS-cog 15/15 Alzheimer's disease 1.2 Aerobic 180 15 Unknown Moderate MASE 15/15 Alzheimer's disease 1.2 Aerobic 180 15 Unknown Moderate DI 15 24 24/30 Moderate Moderate Moderate MMSE 10	Holthoff (2015) ³⁴	30	15/15	Alzheimer's disease	20.6	72.4	Combined	06	12	Unknown	Moderate	MMSE	Yes
261 171/218 MCI 24.5 77.82 Aerobic 90 48 Unknown Moderate ADAS-cog (2011)38 170 85/85 MCI Unknown 68.65 Combined 150 24 Unknown Moderate ADAS-cog 46 237.23 MCI 26.82 69.73 Resistance 180 12 Unknown Moderate ADAS-cog 114 237.23 MCI Alzheimer's disease 180 16 Unknown Moderate MNSE 115 Alzheimer's disease 1.28 81.8 Aerobic 180 15 Unknown Moderate MNSE 10 50.18 Alzheimer's disease 1.28 81.8 Aerobic 90 12 Unknown Moderate on kgn CDT 10 50.50 MCI 26.55 75.3 Combined 180 24 60% Moderate MMSE 10 50.50 MCI 26.55 75.3 Combined	Lam (2015) ³⁷	278	147/131	MCI	25.7	75.45	Aerobic	180	48	Unknown	Low	MMSE	Š
(2011)³¹¹ 170 85/85 MCI Unknown 68.65 (9.73) Combined Resistance 150 24 Unknown Moderate MDAS-cog 46 23/23 MCI 26.82 69.73 Resistance 180 12 Unknown Moderate ADAS-cog 85 36/49 Alzheimer's disease 18.9 76.66 Aerobic 120 12 Unknown Moderate ADAS-cog 914)³² 37 20/17 MCI Unknown 67.7 Aerobic 180 16 Unknown Moderate ADAS-cog 915 30 15/15 Alzheimer's disease 1.40 81.0 Combined 40 48 40%-60% Moderate ADAS-cog 15 Alzheimer's disease 1.28 81.8 Aerobic 180 15 Unknown Moderate to high TCD 10 50/50 MCI 2.53 Combined 180 24 60% Moderate MMSE 50 25/25 MCI <td< td=""><td>Lam (2012)⁵⁷</td><td></td><td>171/218</td><td>MCI</td><td></td><td>77.82</td><td>Aerobic</td><td>06</td><td>48</td><td>Unknown</td><td>Low</td><td>MMSE</td><td>°N</td></td<>	Lam (2012) ⁵⁷		171/218	MCI		77.82	Aerobic	06	48	Unknown	Low	MMSE	°N
46 23/23 MCI 26.82 69.73 Resistance 180 12 Unknown Moderate ADAS-cog 914)38 36/49 Alzheimer's disease 18.9 76.66 Aerobic 120 12 Unknown Moderate MMSE 914)38 37 20/17 MCI Unknown 67.7 Aerobic 180 16 Unknown Moderate MoCA 95 15/15 Alzheimer's disease 1.28 81.8 Aerobic 120 24 50%-80% Moderate to high TCD 16 50,50 MCI 2.18 81.8 Aerobic 120 24 50%-80% Moderate to high TCD 100 50/50 MCI 2.18 68.19 Aerobic 12 24 50%-80% Moderate to high TCD 100 50/50 MCI 2.53 Combined 180 24 60% Moderate Moderate 11)32 40 20/20 Alzheimer's disease<	Lautenschlager (2011) ³¹		85/85	MCI		68.65	Combined	150	24	Unknown	Moderate	ADAS-cog	Yes
85 36/49 Alzheimer's disease 18.9 76.66 Aerobic 120 12 Unknown Moderate MMSE 914)58 37 20/17 MCI Unknown 67.7 Aerobic 180 16 Unknown Moderate MoCA 95 15/15 Alzheimer's disease 1.28 81.8 Aerobic 180 15 Unknown Moderate MMSE 16 54 24/30 Alzheimer's disease Unknown 80.2 Aerobic 120 24 50%-80% Moderate to high TCD 10 50/50 MCI 26.18 Aerobic 90 12 Unknown Moderate CDT 10 50/50 MCI 26.7 76.05 Combined 180 48 60% Moderate MMSE 111)32 40 Alzheimer's disease 22.00 74.1 Combined 210 17.3 Unknown Moderate MMSE 111/32 40 20/20	Lu (2016) ³⁹	-	23/23	MCI	26.82	69.73	Resistance	180	12	Unknown	Moderate	ADAS-cog	Yes
19 4) 58 37 20/17 MCI Unknown G7.7 Aerobic 180 16 Unknown Moderate MoCA 15 15 38 20/18 Alzheimer's disease 14.0 81.0 Combined 40 48 40%-60% Moderate MMSE 15 38 20/18 Alzheimer's disease 12.8 81.8 Aerobic 180 15 Unknown Moderate to high TCD 16 54 24/30 Alzheimer's disease Unknown 80.2 Aerobic 90 12 Unknown Moderate CDT 100 50/50 MCI 26.55 75.3 Combined 180 48 60% Moderate MMSE 50 25/25 MCI 26.7 76.05 Combined 110 17.3 Unknown Moderate MMSE 11)32 40 20/20 Alzheimer's disease 22.00 74.1 Combined 210 17.3 Unknown Moderate MMSE 60 30/30 MCI 24.67 60 Aerobic 120 2	Miu (2008)³º	82	36/49	Alzheimer's disease		99.9/	Aerobic	120	12	Unknown	Moderate	MMSE	°Z
30 15/15 Alzheimer's disease 14.0 81.0 Combined 40 48 40%—60% Moderate MMSE 38 20/18 Alzheimer's disease 12.8 81.8 Aerobic 180 15 Unknown Moderate ERFC 44 32/12 Metabolic syndrome 26.18 68.19 Aerobic 120 24 50%—80% Moderate to high TCD 45 24/30 Alzheimer's disease Unknown 80.2 Aerobic 90 12 Unknown Moderate 50 25/25 MCI 26.55 75.3 Combined 180 24 60% Moderate MMSE 51 15/10 Alzheimer's disease Unknown 81.65 Combined 180 12 Unknown Moderate MMSE 52 15/10 Alzheimer's disease 22.00 74.1 Combined 210 17.3 Unknown Moderate MMSE 60 30/30 MCI 24.67 66 Aerobic 120 24 Unknown Moderate MMSE	Nascimento (2014) ⁵⁸	37	20/17	MCI		67.7	Aerobic	180	91	Unknown	Moderate	MoCA	Yes
155 38 20/18 Alzheimer's disease 12.8 81.8 Aerobic 180 15 Unknown Moderate ERFC 44 32/12 Metabolic syndrome 26.18 68.19 Aerobic 120 24 50%–80% Moderate to high TCD 45 24/30 Alzheimer's disease Unknown 80.2 Aerobic 90 12 Unknown Moderate CDT 46 55 25/25 MCI 26.55 75.3 Combined 180 24 60% Moderate MMSE 50 25/25 MCI 26.7 76.05 Combined 180 48 60% Moderate MMSE 51 15/10 Alzheimer's disease Unknown 81.65 Combined 210 17.3 Unknown Moderate MMSE 52 15/10 Alzheimer's disease 22.00 74.1 Combined 210 17.3 Unknown Moderate MMSE 60 30/30 MCI 24.67 66 Aerobic 120 24 Unknown Moderate MMSE	Kwak (2008) ⁵⁶	30	15/15	Alzheimer's disease	14.0	81.0	Combined	40	48	40%–60%	Moderate	MMSE	Yes
44 32/12 Metabolic syndrome 26.18 68.19 Aerobic 120 24 50%-80% Moderate to high TCD 100 50/50 MCI 26.55 75.3 Combined 180 24 60% Moderate CDT 50 25/25 MCI 26.55 75.3 Combined 180 48 60% Moderate MMSE 25 15/10 Alzheimer's disease Unknown 81.65 Combined 210 12 Unknown Moderate MMSE 21)1) ⁵² 40 20/20 Alzheimer's disease 22.00 74.1 Combined 210 17.3 Unknown Moderate MMSE 60 30/30 MCI 24.67 66 Aerobic 120 24 Unknown Moderate MMSE	Kemoun (2010) ⁵⁵	38	20/18	Alzheimer's disease		8.18	Aerobic	180	15	Unknown	Moderate	ERFC	Yes
 54 24/30 Alzheimer's disease Unknown 80.2 Aerobic 90 12 Unknown Moderate CDT 100 50/50 MCI 26.55 75.3 Combined 180 24 60% Moderate MMSE 50 25/25 MCI 26.7 76.05 Combined 180 48 60% Moderate MMSE 515/10 Alzheimer's disease Unknown 81.65 Combined 210 12 Unknown Moderate MMSE 50 20/20 Alzheimer's disease 22.00 74.1 Combined 210 17.3 Unknown Moderate MMSE 50 20/20 MCI 24.67 66 Aerobic 120 24 Unknown Moderate MMSE 	Kim (2011) ³⁶	44	32/12	Metabolic syndrome		68.19	Aerobic	120	24	20%-80%	Moderate to high		°
100 50/50 MCI 26.55 75.3 Combined 180 24 60% Moderate MMSE 50 25/25 MCI 26.7 76.05 Combined 180 48 60% Moderate MMSE 25 15/10 Alzheimer's disease Unknown 81.65 Combined 210 12 Unknown Moderate MMSE 911)52 40 20/20 Alzheimer's disease 22.00 74.1 Combined 210 17.3 Unknown Moderate MMSE 60 30/30 MCI 24.67 66 Aerobic 120 24 Unknown Moderate MMSE	Stevens (2016) ⁴⁶	54	24/30	Alzheimer's disease	L W	80.2	Aerobic	90	12	Unknown	Moderate	CDT	Yes
50 25/25 MCI 26.7 76.05 Combined 180 48 60% Moderate MMSE 25 15/10 Alzheimer's disease Unknown 81.65 Combined 210 12 Unknown Moderate MMSE 40 20/20 Alzheimer's disease 22.00 74.1 Combined 210 17.3 Unknown Moderate MMSE 60 30/30 MCI 24.67 66 Aerobic 120 24 Unknown Moderate MMSE	Suzuki (2013) ⁴⁷	00	20/20	MCI	26.55	75.3	Combined	180	24	%09	Moderate	MMSE	°
25 15/10 Alzheimer's disease Unknown 81.65 Combined 210 12 Unknown Moderate MMSE 40 20/20 Alzheimer's disease 22.00 74.1 Combined 210 17.3 Unknown Moderate MMSE 60 30/30 MCI 24.67 66 Aerobic 120 24 Unknown Moderate MMSE	Suzuki (2012) ⁴⁸	20	25/25	MCI	26.7	76.05	Combined	180	48	%09	Moderate	MMSE	Yes
40 20/20 Alzheimer's disease 22.00 74.1 Combined 210 17.3 Unknown Moderate MMSE 60 30/30 MCI 24.67 66 Aerobic 120 24 Unknown Moderate MMSE	Van (2004) ⁵⁰	25	15/10	Alzheimer's disease		81.65	Combined	210	12	Unknown	Moderate	MMSE	Yes
60 30/30 MCI 24.67 66 Aerobic 120 24 Unknown Moderate MMSE	Vreugdenhil (2011) ⁵²	40	20/20	Alzheimer's disease	22.00	74.1	Combined	210	17.3	Unknown	Moderate	MMSE	Yes
	Wei (2014) ⁵³	09	30/30	MCI		99	Aerobic	120	24	Unknown	Moderate	MMSE	Yes

Abbreviations: ACE-R, Addenbrooke's Cognitive Examination-Revised: ADAS-cog, Alzheimer's Disease Assessment Scale-cognitive subscale; BCPT-CPS, Breast Cancer Prevention Trial Symptom Checklist-Cognitive Problems Scale; BDI-cog, Beck Depression Inventory-cognitive; CDT, clock drawing test; EORTC-cog, European Organization for Research and Treatment of Cancer-cognitive; ERFC, Rapid Evaluation of Cognitive Function; FAB, Frontal Assessment Battery; FACS, functional assessment of communication skills; HR_{max}, maximum heart rate; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; PFS-cog, Piper Fatigue Scalecognitive; SLCT, six-letter cancellation test; TCD, total cognitive domain.

was assessed using Higgins I^2 values. The significance level was set at P<0.05.

Results

Study search and selection

We identified 12,174 studies based on the database searches; 962 articles were excluded because of duplicate records. Based on title and abstract, we excluded 11,135 studies. The full-text papers of 77 studies were reviewed and 42 studies were excluded. These studies were excluded because they did not assess exercise interventions, reported incomplete data, their control group underwent an exercise intervention, or they did not report cognitive function as an outcome measurement. Finally, 35 studies with 3,113 participants were included in the final analysis (Figure 1).^{24–58}

Description of studies

The characteristics of the included articles are stated in Table 1. In the included studies, the sample size ranged from 20²⁴ to 278³⁷ participants. Thirteen studies examined the effect of exercise on cognitive function in patients with Alzheimer's disease. 24,25,27,28,30,34,43,46,50,52,54-56 Nine studies examined the effect of exercise on cognitive function in patients with mild cognitive impairment. 33,37-39,47,48,53,57,58 Five studies examined the effect of exercise on cognitive function in patients with cancer. 29,35,42,45,49 One study examined the effect of exercise on cognitive function in patients with Parkinson's disease. 32 One study examined the effect of exercise on cognitive function in patients with heart failure. 40 One study examined the effect of exercise on cognitive function in patients with stroke.⁴¹ One study examined the effect of exercise on cognitive function in patients with metabolic syndrome.³⁶ One study examined the effect of exercise on cognitive function in patients with osteoarthritic knee. 44 And one study examined the effect of exercise on cognitive function in patients with fibromyalgia.³¹ One study examined the effect of exercise on cognitive function in patients with climacteric syndrome.²⁶ The mean baseline MMSE ranged from 5.828 to 28.7,33 excluding 11 studies that did not report baseline MMSE. The mean age ranged from 47.5 years⁴⁹ to 82.5 years.²⁸ The interventions were then divided into three exercise modes: aerobic, resistance, and a combination of aerobic and resistance, according to the American College of Sports Medicine. 59 The frequency of the exercise intervention varied from 40 min⁵⁶ to 300 min²⁶ per week. The duration of the total training period varied from 6 weeks35,49 to 60 weeks.25 Fitness level was divided into three modes: low, moderate, and high, according to the American College of Sports Medicine.⁶⁰

Seventeen studies used the MMSE, ^{24,25,27,30,34,37,40,44,47,48}, ^{50–54,56,57} three studies used the ADAS-cog, ^{33,38,39} three studies used the EORTC questionnaire, ^{42,45,49} two studies used the CDT, ^{43,46} one study used the FAB, ³² one study used the ACE-R, ⁴¹ one study used the BOPI-cog, ²⁹ one study used the BDI-cog, ³¹ one study used the PFS-cog, ³⁵ one study used the FACS, ²⁸ one study used the SLCT, ²⁶ one study used the MoCA, ⁵⁸ one study used the ERFC, ⁵⁵ and one study used the TCD assessment tool. ³⁶ These different tools were applied to evaluate the same cognitive domain within a study or between studies.

Among the included studies, three studies compared two intervention types with a control group (Table 1).^{32,43,51}

Quality assessment

Thirty-five studies were included in the quality assessment. The assessment of bias in each domain across the included studies is shown in Table 2. The quality of the majority of the studies was moderate, with a mean score of 22.05. Four studies were rated as of poor quality, 18 studies were deemed to be of moderate quality, and 13 studies were deemed to be of good quality.

Main analysis: effects of exercise intervention on cognitive function

Thirty-five studies with 3,113 participants evaluated the effect of exercise on cognitive function in patients with chronic diseases.^{24–58} The main analysis revealed a positive overall random effect of the exercise interventions on cognitive function in patients with chronic diseases (Table 3).

Secondary analyses

Types of disease

Thirteen studies containing 958 participants examined the effect of exercise on cognitive function in patients with Alzheimer's disease. ^{24,25,27,28,30,34,43,46,50,52,54–56} We found positive overall random effect of exercise intervention on cognitive function in studies evaluating Alzheimer's disease patients. Nine studies containing 1,117 participants examined the effect of exercise on cognitive function in patients with MCI. ^{33,37–39,47,48,51,53,57,58} In these studies, the difference observed in postintervention cognitive function did not differ between the exercise group and the control group. Five studies containing 502 participants examined the effect of exercise on cognitive function in patients with cancer. ^{29,35,42,45,49} In these studies, the difference observed in postintervention cognitive function did not differ between the exercise group and the control group in cancer patients.

Cai et al Dovepress

Table 2 Quality of included studies

First author (year)	Reporting	External validity	Bias	Confounding	Power	Total	Quality as per
	(11 points)	(3 points)	(7 points)	(6 points)	(5 points)	(32 points)	cutoff described
Arcoverde (2013) ²⁴	10	3	6	3	5	27	Good
Oh (2012) ⁴²	10	3	5	3	5	26	Good
Tsai (2013)44	8	3	5	3	0	19	Moderate
Moore (2015)41	9	3	6	1	5	24	Good
Derry (2015) ²⁹	8	2	5	2	5	17	Poor
Varela (2011)51	8	3	5	3	0	19	Moderate
Hildreth (2015)33	8	2	5	4	0	16	Poor
Lindsay (2014) ⁴⁰	8	3	5	4	0	20	Moderate
Vadiraja (2009)49	10	2	5	4	0	21	Moderate
Schimidt (2015) ⁴⁵	9	3	5	4	0	21	Moderate
Gowans (2001)31	9	3	5	4	5	26	Good
Kim (2005) ³⁵	9	2	5	3	0	19	Moderate
Ohman (2016) ⁴³	9	2	5	5	0	21	Moderate
Cancela (2016) ²⁵	9	3	5	4	5	27	Good
Chattha (2008) ²⁶	9	3	5	3	5	25	Good
Cheng (2014) ²⁷	9	3	5	4	5	26	Good
Cott (2002) ²⁸	9	2	5	3	0	19	Moderate
Christofoletti (2008) ⁵⁴	7	2	5	2	0	16	Poor
Hashimoto (2015) ³²	9	2	5	1	5	22	Moderate
Holthoff (2015) ³⁴	9	2	5	2	5	23	Moderate
Lam (2015) ³⁷	10	2	6	4	0	22	Moderate
Lam (2012) ⁵⁷	8	3	5	3	0	19	Moderate
Lautenschlager (2011) ³⁸	9	2	5	3	5	24	Good
Lu (2016) ³⁹	9	2	5	3	5	24	Good
Miu (2008) ³⁰	10	2	6	4	5	27	Good
Nascimento (2014) ⁵⁸	8	2	5	2	0	17	Poor
Kwak (2008) ⁵⁶	9	1	5	4	5	24	Moderate
Kemoun (2010) ⁵⁵	7	3	5	2	5	22	Moderate
Kim (2011) ³⁶	9	3	6	3	5	26	Good
Stevens (2016)46	8	2	5	3	0	18	Moderate
Suzuki (2013) ⁴⁷	9	2	5	4	0	20	Moderate
Suzuki (2012) ⁴⁸	9	2	5	4	5	25	Good
Van (2004)50	8	2	5	3	5	23	Moderate
Vreugdenhil (2011) ⁵²	9	3	5	4	5	26	Good
Wei (2014) ⁵³	7	2	5	2	5	21	Moderate

Three studies assessed the effect of exercise intervention on cognitive function in patients with osteoarthritic knee,⁴⁴ heart failure,⁴⁰ and metabolic syndrome.³⁶ In these studies, the difference observed in postintervention cognitive function did not differ between the exercise and control groups. Four studies evaluated the effect of exercise on cognitive function in patients with fibromyalgia,³¹ stroke,⁴¹ Parkinson's disease,³² and climacteric syndrome,²⁶ and the results of these studies indicated that exercise had a positive effect on cognitive function.

Types of exercise intervention

Twenty-three studies containing 2,120 participants examined the effect of aerobic exercise on cognitive function in patients with chronic disease. ^{24–33,35–37,40,42,44,46,49,51,53,55,57,58} Five studies containing 261 participants examined the effect of resistance exercise on cognitive function in patients

with chronic disease. ^{32,39,41,45,54} Eight studies containing 725 participants examined the effect of combined exercise on cognitive function in patients with chronic disease. ^{34,38,43,47,48,50,52,56} We identified an overall positive random effect for aerobic exercise interventions but not for resistance exercise interventions and combined exercise interventions. Twenty-seven studies containing 2,845 participants examined the effect of interventions including aerobic exercise (both combined exercise and aerobic exercise intervention) on cognitive function in patient with chronic disease. ^{24–38,40,42–44,46–53,55–58} We identified positive overall random effect for the included aerobic exercise interventions.

Frequency of exercise intervention

According to the World Health Organization recommendations, a weekly schedule of 150 min exercise was used to distinguish between high- and low-frequency interventions.⁶¹

Table 3 Meta-analysis of effect of exercise on cognitive function

Parameters	Included studies	N	P-value	ı	Z	SMD (95% CI)
Main outcome	35	3,113	0.0007	74%	3.41	0.26 (0.11, 0.41)
Types of disease						,
Alzheimer's disease	13	958	0.004	77%	2.88	0.42 (0.14, 0.71)
Mild cognitive impairment	9	1,117	0.21	77%	1.25	0.17 (-0.10, 0.44)
Cancer	5	502	0.66	86%	0.44	0.11 (-0.39, 0.61)
Types of exercise intervention						
Aerobic	23	2,120	0.0008	70%	3.34	0.29 (0.12, 0.47)
Resistance	5	261	0.69	73%	0.40	0.10 (-0.39, 0.59)
Combined	8	725	0.14	83%	1.46	0.29 (-0.10, 0.67)
Aerobic included	31	2,845	0.0005	75%	3.47	0.28 (0.12, 0.45)
Frequency of exercise intervention						
High frequency	18	1,494	0.07	83%	1.82	0.25 (-0.02, 0.52)
High frequency (excluded resistance)	16	1,450	0.02	82%	2.24	0.31 (0.04, 0.57)
Low frequency	16	1,547	0.0008	40%	2.67	0.19 (0.05, 0.33)
Low frequency (excluded resistance)	14	1,409	0.15	60%	1.43	0.13 (-0.05, 0.32)
Intensity of exercise intervention						
Low	13	1,609	0.03	77%	2.12	0.24 (0.02, 0.47)
Moderate	21	1,322	0.03	72%	2.13	0.24 (0.02, 0.46)
Moderate (excluded resistance)	19	1,199	0.008	76%	2.66	0.34 (0.09, 0.59)
High	2	138	0.30	0%	1.04	0.18 (-0.16, 0.51)

Abbreviations: CI, confidence interval; SMD, standardized mean difference.

Eighteen studies containing 1,494 participants examined the effect of high-frequency exercise intervention on cognitive function in patients with chronic disease. 26-28,33,35,37-40,42,47-50, 52,54,55,58 Sixteen studies containing 1,547 participants examined the effect of low-frequency exercise intervention on cognitive function in patients with chronic disease. 24,25,29-32, 34,36,43-46,51,53,56,57 We identified a positive overall random effect for low-frequency interventions but not for high-frequency interventions. Further investigations revealed that after the exclusion of resistance exercise interventions, the effect of low-frequency exercise interventions was not significant. Further investigations revealed that after the exclusion of resistance interventions, the effect of the high-frequency exercise interventions was significant. Moore et al41 examined the effect of an intervention including 135–180 min of weekly exercise on cognitive function in patients with stroke and found that the exercise intervention did not have an effect on cognitive function.

Intensity of exercise intervention

Thirteen studies containing 1,609 participants examined the effect of low-intensity exercise intervention on cognitive function in patients with chronic diseases. ^{25–29,35,37,42–44,49,51,57} Twenty-one studies containing 1,322 participants examined the effect of moderate-intensity exercise intervention on cognitive function in patients with chronic diseases. ^{24,30–33,38–40,43,46–48,50–56,58} Two studies containing 138 participants examined the effect of high-intensity exercise intervention

on cognitive function in patients with chronic diseases. 41,45 We found positive random effects for low-intensity and moderate-intensity exercise interventions but not for high-intensity exercise interventions. Further investigations revealed that after the exclusion of resistance interventions, the effect of moderate-intensity exercise intervention on the cognitive function was significant.

Discussion

In this meta-analysis of randomized controlled trials, we identified a positive overall effect of exercise interventions on cognitive function in patients with chronic diseases. Aerobic exercise interventions were found to have a positive effect on cognitive function in patients with chronic disease. In addition, the effect of exercise on cognitive function was independent of the presence of Alzheimer's disease. Furthermore, we found that low-frequency exercise interventions had a positive effect on cognitive function in chronic disease patients. Finally, we observed positive effects of low-intensity and moderate-intensity exercise intervention on cognitive function in chronic disease patients.

In this meta-analysis and systematic review, we found that the exercise interventions were beneficial in the current sample of chronic disease patients. Exercise has been reported to cause physiological state changes that disrupt brain homeostasis.⁴¹ The brain has been found to modify its resource allocation in response to these changes. Studies have suggested that maintenance of physical activity may

be associated with increased neural resources in some brain regions and reduced neural resources in other brain regions. ^{47,58,62} Exercise affects cognitive function by causing a significant reduction in the peripheral concentrations of IL-6 and TNF-α, as well as a significant increase in peripheral levels of BDNF in individuals with chronic diseases. ⁵⁸ Exercise also leads to structural changes in the brain, such as increases in dendritic length and branching and hippocampal neurogenesis, ⁶² as well as maintains the atrophy levels of the whole brain cortex. ⁴⁷

Cognition is a complex term that includes various domains. Some studies have proposed relationships between specific exercise regimens and specific cognitive domains in chronic disease patients. Aerobic exercise has been reported to contribute to further beneficial effects on the memory domain. 32,36,48 The results of an animal study investigating the effects of 12 weeks of voluntary running on the restoration of place recognition memory in 20-month-old rats emphasized the unique synaptic effects of exercise on the aged brain and their specific relevance to the hippocampal-based system for place recognition memory.⁶³ Dancing involves paying attention to music and signals while envisaging the next movement, and these feature may help patients to perform better in the verbal fluency category.⁵⁰ Lu et al³⁹ found that variations in position changes and movement configurations during dumbbell-training sessions were associated with changes in the spatiotemporal orientation, selective attention, and executive control of participants.

The results of our study showed that aerobic exercise interventions had a positive effect on cognitive function. This result was consistent with the recommendations of the World Health Organization for a weekly minimum of 150 min of moderate-intensity aerobic or 75 min of vigorous-intensity aerobic activity with additional musclestrengthening exercises.⁶¹ Two meta-analyses of the effect of aerobic exercise on cognitive function found that aerobic exercise improved cognitive function. 19,20 These results were similar to the results of our study. Aerobic exercises improve the maximum oxygen uptake and increase and redistribute cerebral blood flow, enhance antioxidant action via repair enzymes and proinflammatory cytokines, as well as increase beta-amyloid degradation, levels of neurotrophic factors, neurogenesis, and angiogenesis. 24,58 In this metaanalysis, we did not find resistance exercises to have an effect on cognitive function in chronic disease patients, which may be due to the difficulties related to controlling for some methodological and sampling biases and the short follow-up periods.54

In this meta-analysis and systematic review, we found that exercise interventions were beneficial for cognitive function in Alzheimer's disease patients. The results of this study were similar to those of previous studies that reported that exercise has a positive effect on cognitive function in Alzheimer disease patients. 19,64,65 These trends may indicate that the practice of regular physical exercise might contribute to slower declines in cognitive function. In our study, the exercise interventions were not found to have a positive effect on cognitive function in patients with MCI. There may be insufficient evidence for an effect of exercise intervention on MCI patients. A meta-analysis and systematic review of the effect of aerobic exercise on cognitive function in older adults with MCI showed that aerobic exercise significantly improved global cognitive ability (MMSE scores: MD =0.98, 95% CI: 0.5-1.45; P<0.0001). ²⁰ The cited meta-analysis and systematic review evaluated interventions encompassing the practice of any aerobic exercises regardless of the style (eg, yoga, Tai Chi, or treadmill) for at least 4 weeks, with >1 exercise session per week. In addition, the outcomes assessed included global cognitive ability and any specific domains of cognition assessed in the aforementioned meta-analysis. Our meta-analysis and systematic review was not restricted by type of exercise, and the outcome of interest was global cognitive function. In our study, the exercise intervention was not found to have a positive effect on cognitive function in patients with cancer. The studies that assessed the effects of exercise interventions on cognitive function in cancer patients all provided data for short-term interventions that did not exceed 12 weeks.

In this meta-analysis and systematic review, we found that low-frequency exercise intervention was beneficial in chronic disease patients. The studies providing low-frequency exercise intervention all exceeded 12 weeks' duration, and two studies even exceeded 48 weeks' duration. ^{25,43} The beneficial effect of low-frequency exercise on cognitive function may be associated with a good performance of the functional capacity. ²⁴ Additionally, all the included studies of low-frequency exercise interventions were of good methodological quality.

The American College of Sports Medicine has suggested that moderate-intensity physical exercise may lead to significant changes in brain health and cognitive performance, with potential effects on a broad range of cognitive domains. 66 In this meta-analysis and systematic review, we found that both low-intensity and moderate-intensity exercise interventions appeared to be effective in improving cognitive function in chronic disease patients. Moderate-intensity exercise might

be an effective alternative to reduce the level of systemic inflammation and decrease cognitive decline. Additionally, most of the studies evaluating moderate-intensity exercise were of good methodological quality. The included studies indicated that low-intensity exercise such as Tai Chi^{27,42,44} or yoga²⁹ exerted positive effects on cognitive function. Patients involved in low-exercise intensity interventions demonstrated more notable changes in physical functioning, contributing to the positive effects observed in psychological well-being. Lower levels of distress and fatigue may have contributed to the beneficial effects of low-intensity exercise interventions on cognitive function.

Limitations

This study had some limitations. First, the weekly duration of exercise intervention used in the included studies varied from 40 min to 300 min per week, and the overall duration of the exercise intervention used in the included studies varied from 6 weeks to 60 weeks. These differences may have affected the relationship observed between the specific types of exercise and improvements in the evaluated cognitive domains. Second, it was not possible to blind participants to the exercise intervention. Therefore, performance bias may have been unavoidable.

Conclusion

The findings of this meta-analysis support the efficacy of exercise interventions in improving cognitive function in individuals affected by chronic disease. Beneficial effects were observed independent of the type of clinical disease, type of exercise, frequency, and intensity of the exercise intervention.

Acknowledgment

This work was supported by the Youth Program of Health and Family Planning Commission of Jilin Province (grant number 2015Q022).

Disclosure

The authors report no conflicts of interest in this work.

References

- Wang C, Collet JP, Lau J. The effect of Tai Chi on health outcomes in patients with chronic conditions: a systematic review. *Arch Intern Med*. 2004;164(5):493–501.
- 2. Graff-Radford NR. Can aerobic exercise protect against dementia? *Alzheimers Res Ther*. 2011;3(1):1–6.
- Kirk-Sanchez NJ, McGough EL. Physical exercise and cognitive performance in the elderly: current perspectives. Clin Interv Aging. 2014;9: 51–62.

- Nelson ME, Rejeski WJ, Blair SN, et al; American College of Sports Medicine; American Heart Association. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. *Circulation*. 2007;116(9):1094–1105.
- Hess LM, Huang HQ, Hanlon AL, et al. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: an NRG oncology/gynecologic oncology group study. *Gynecol Oncol*. 2015;139(3):541–545.
- Caspersen CJ, Powell KE, Christenson GM. Physical activity, exercise, and physical fitness: definitions and distinctions for health-related research. *Public Health Rep.* 1985;100(2):126–131.
- Radak Z, Hart N, Sarga L, et al. Exercise plays a preventive role against Alzheimer's disease. J Alzheimers Dis. 2010;20(3):777–783.
- Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. *J Neurosci*. 2005;25(17):4217–4221.
- Sahay A, Scobie KN, Hill AS, et al. Increasing adult hippocampal neurogenesis is sufficient to improve pattern separation. *Nature*. 2011; 472(7344):U466–U539.
- Kronenberg G, Bick-Sander A, Bunk E, Wolf C, Ehninger D, Kempermann G. Physical exercise prevents age-related decline in precursor cell activity in the mouse dentate gyrus. *Neurobiol Aging*. 2006; 27(10):1505–1513.
- Ding YH, Luan XD, Li J, et al. Exercise-induced overexpression of angiogenic factors and reduction of ischemia/reperfusion injury in stroke. Curr Neurovasc Res. 2004;1(5):411–420.
- Leem YH, Lim HJ, Shim SB, Cho JY, Kim BS, Han PL. Repression of tau hyperphosphorylation by chronic endurance exercise in aged transgenic mouse model of tauopathies. *J Neurosci Res.* 2009;87(11):2561–2570.
- Belarbi K, Burnouf S, Fernandez-Gomez FJ, et al. Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like tau pathology. *Neurobiol Dis*. 2011;43(2):486–494.
- Um HS, Kang EB, Koo JH, et al. Treadmill exercise represses neuronal cell death in an aged transgenic mouse model of Alzheimer's disease. *Neurosci Res.* 2011;69(2):161–173.
- Buchman AS, Boyle PA, Yu L, Shah RC, Wilson RS, Bennett DA. Total daily physical activity and the risk of AD and cognitive decline in older adults. *Neurology*. 2012;78(17):1323–1329.
- Hamer M, Chida Y. Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. *Psychol Med*. 2009;39(1):3–11.
- Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. *JAMA*. 2009;302(6):627–637.
- Sofi F, Valecchi D, Bacci D, et al. Physical activity and risk of cognitive decline: a meta-analysis of prospective studies. *J Intern Med.* 2011; 269(1):107–117.
- Groot C, Hooghiemstra AM, Raijmakers PG, et al. The effect of physical activity on cognitive function in patients with dementia: a meta-analysis of randomized control trials. Ageing Res Rev. 2016;25:13–23.
- Zheng G, Xia R, Zhou W, Tao J, Chen L. Aerobic exercise ameliorates cognitive function in older adults with mild cognitive impairment: a systematic review and meta-analysis of randomised controlled trials. *Br J Sports Med*. 2016;50:1443–1450.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol*. 2009;62(10):1006–1012.
- Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and nonrandomised studies of healthcare interventions. *J Epidemiol Community Health*. 1998;52(6):7.
- 23. Higgins JPT. Cochrane Handbook for Systematic Reviews of Interventions Version. London: The Cochrane Collaboration; 2011.
- Arcoverde C, Deslandes A, Moraes H, et al. Treadmill training as an augmentation treatment for Alzheimer's disease: a pilot randomized controlled study. Arg Neuropsiquiatr. 2014;72(3):190–196.

Cai et al Dovepress

 Cancela JM, Ayan C, Varela S, Seijo M. Effects of a long-term aerobic exercise intervention on institutionalized patients with dementia. *Med Sci Sports Sci.* 2016;19(4):293–298.

- Chattha R, Nagarathna R, Padmalatha V, Nagendra HR. Effect of yoga on cognitive functions in climacteric syndrome: a randomised control study. BJOG. 2008;115(8):991–1000.
- Cheng ST, Chow PK, Song YQ, et al. Mental and physical activities delay cognitive decline in older persons with dementia. *Am J Geriatr Psychiatry*. 2014;22(1):63–74.
- Cott CA, Dawson P, Sidani T, Wells T. The effects of a walking/talking program on communication, ambulation, and functional status in residents with Alzheimer disease. Alzheimer Dis Assoc Disord. 2002;16(2):81–87.
- Derry HM, Jaremka LM, Bennett JM, et al. Yoga and self-reported cognitive problems in breast cancer survivors: a randomized controlled trial. *Psychooncology*. 2015;24(8):958–966.
- DKY Miu SS, Mak YF. A randomised controlled trial on the effect of exercise on physical, cognitive and affective function in dementia subjects. *Asian J Gerontol Geriatr*. 2008;3:8–16.
- Gowans SE, deHueck A, Voss S, Silaj A, Abbey SE, Reynolds WJ. Effect of a randomized, controlled trial of exercise on mood and physical function in individuals with fibromyalgia. *Arthritis Rheum*. 2001; 45(6):519–529.
- Hashimoto H, Takabatake S, Miyaguchi H, Nakanishi H, Naitou Y. Effects of dance on motor functions, cognitive functions, and mental symptoms of Parkinson's disease: a quasi-randomized pilot trial. Complement Ther Med. 2015;23(2):210–219.
- 33. Hildreth KL, Van Pelt RE, Moreau KL, et al. Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: a pilot study. *Dement Geriatr Cogn Dis Extra*. 2015;5(1): 51–63.
- Holthoff VA, Marschner K, Scharf M, et al. Effects of physical activity training in patients with Alzheimer's dementia: results of a pilot RCT study. PLoS One. 2015;10(4):e0121478.
- Kim SD, Kim HS. Effects of a relaxation breathing exercise on fatigue in haemopoietic stem cell transplantation patients. *J Clin Nurs*. 2005;14(1):51–55.
- Kim SH, Kim M, Ahn YB, et al. Effect of dance exercise on cognitive function in elderly patients with metabolic syndrome: a pilot study. *J Sports Sci Med*. 2011;10(4):671–678.
- Lam LCW, Chan WC, Leung T, Fung AWT, Leung EMF. Would older adults with mild cognitive impairment adhere to and benefit from a structured lifestyle activity intervention to enhance cognition? A cluster randomized controlled trial. *PLoS One*. 2015;10(3):e0118173.
- Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: a randomized trial. *JAMA*. 2009;301(3):1027–1037.
- Lu JJ, Sun MY, Liang LC, Feng Y, Pan XY, Liu Y. Effects of momentum-based dumbbell training on cognitive function in older adults with mild cognitive impairment: a pilot randomized controlled trial. *Clin Interv Aging*. 2016;11:9–16.
- Miller LA. The longitudinal effects of cardiac rehabilitation on cognition in older adults with heart failure [dissertation]. Kent: Kent State University; 2014.
- Moore SA, Hallsworth K, Jakovljevic DG, et al. Effects of community exercise therapy on metabolic, brain, physical, and cognitive function following stroke: a randomized controlled pilot trial. *Neurorehabil Neural Repair*. 2015;29(7):623–635.
- Oh B, Butow PN, Mullan BA, et al. Effect of medical Qigong on cognitive function, quality of life, and a biomarker of inflammation in cancer patients: a randomized controlled trial. Support Care Cancer. 2012;20(6):1235–1242.
- Ohman H, Savikko N, Strandberg TE, et al. Effects of exercise on cognition: the Finnish Alzheimer disease exercise trial: a randomized, controlled trial. *J Am Geriatr Soc.* 2016;64(4):731–738.
- 44. Tsai PF, Chang JY, Beck C, Kuo YF, Keefe FJ. A pilot cluster-randomized trial of a 20-Week Tai Chi Program in elders with cognitive impairment and osteoarthritic knee: effects on pain and other health outcomes. J Pain Symptom Manage. 2013;45(4):660–669.

45. Schmidt ME, Wiskemann J, Armbrust P, Schneeweiss A, Ulrich CM, Steindorf K. Effects of resistance exercise on fatigue and quality of life in breast cancer patients undergoing adjuvant chemotherapy: a randomized controlled trial. *Int J Cancer*. 2015;137(2):471–480.

- Stevens J, Killeen M. A randomised controlled trial testing the impact of exercise on cognitive symptoms and disability of residents with dementia. *Contemp Nurse*. 2006;21(1):32–40.
- Suzuki T, Shimada H, Makizako H, et al. A randomized controlled trial of multicomponent exercise in older adults with mild cognitive impairment. *PLoS One*. 2013;8(4):e61483.
- Suzuki T, Shimada H, Makizako H, et al. Effects of multicomponent exercise on cognitive function in older adults with amnestic mild cognitive impairment: a randomized controlled trial. *BMC Neurol*. 2012;12:128.
- Vadiraja HS, Rao MR, Nagarathna R, et al. Effects of yoga program on quality of life and affect in early breast cancer patients undergoing adjuvant radiotherapy: a randomized controlled trial. *Complement Ther Med*. 2009;17(5–6):274–280.
- 50. Van de Winckel A, Feys H, De Weerdt W, Dom R. Cognitive and behavioural effects of music-based exercises in patients with dementia. *Clin Rehabil*. 2004;18(3):253–260.
- Varela S, Ayan C, Cancela JM, Martin V. Effects of two different intensities of aerobic exercise on elderly people with mild cognitive impairment: a randomized pilot study. Clin Rehabil. 2012;26(5):442–450.
- Vreugdenhil A, Cannell J, Davies A, Razay G. A community-based exercise programme to improve functional ability in people with Alzheimer's disease: a randomized controlled trial. *Scand J Caring Sci*. 2012;26(1):12–19.
- Wei XH, Ji LL. Effect of handball training on cognitive ability in elderly with mild cognitive impairment. *Neurosci Lett.* 2014;566:98–101.
- Christofoletti G, Oliani MM, Gobbi S, Stella F, Bucken Gobbi LT, Renato Canineu P. A controlled clinical trial on the effects of motor intervention on balance and cognition in institutionalized elderly patients with dementia. *Clin Rehabil*. 2008;22(7):618–626.
- Kemoun G, Thibaud M, Roumagne N, et al. Effects of a physical training programme on cognitive function and walking efficiency in elderly persons with dementia. *Dement Geriatr Cogn Disord*. 2010;29(2): 109–114.
- Kwak YS, Um SY, Son TG, Kim DJ. Effect of regular exercise on senile dementia patients. *Int J Sports Med*. 2008;29(6):471–474.
- 57. Lam LCW, Chau RCM, Wong BML, et al. A 1-year randomized controlled trial comparing mind body exercise (Tai Chi) with stretching and toning exercise on cognitive function in older Chinese adults at risk of cognitive decline. *J Am Med Dir Assoc*. 2012;13(6): 568.e15–568.e20.
- Nascimento CMC, Pereira JR, de Andrade LP, et al. Physical exercise in MCI elderly promotes reduction of pro-inflammatory cytokines and improvements on cognition and BDNF peripheral levels. *Curr Alzheimer Res.* 2014;11(8):799–805.
- American College of Sports Medicine, Chodzko-Zajko WJ, Proctor DN, et al. American College of Sports Medicine position stand. Exercise and physical activity for older adults. *Med Sci Sports Exerc*. 2009; 41(7):1510–1530.
- Thompson PD, Arena R, Riebe D, Pescatello LS. ACSM's new preparticipation health screening recommendations from ACSM's guidelines for exercise testing and prescription, ninth Edition. *Curr Sports Med Rep.* 2013;12(4):215–217.
- Organization WH. Global Recommendations on Physical Activity for Health. Geneva: World Health Organization; 2015.
- Swain RA, Harris AB, Wiener EC, et al. Prolonged exercise induces angiogenesis and increases cerebral blood volume in primary motor cortex of the rat. *Neuroscience*. 2003;117(4):1037–1046.
- Siette J, Westbrook RF, Cotman C, et al. Age-specific effects of voluntary exercise on memory and the older brain. *Biol Psychiatry*. 2013; 73(5):435–442.
- 64. Farina N, Rusted J, Tabet N. The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review. *Int Psychogeriatr.* 2014;26(1):9–18.

- Heyn P, Abreu BC, Ottenbacher KJ. The effects of exercise training on elderly persons with cognitive impairment and dementia: a metaanalysis. Arch Phys Med Rehabil. 2004;85(10):1694–1704.
- American College of Sports Medicine Position Stand. Exercise and physical activity for older adults. *Phys Sportsmed*. 1999;27(11):115.

Clinical Interventions in Aging

Publish your work in this journal

Clinical Interventions in Aging is an international, peer-reviewed journal focusing on evidence-based reports on the value or lack thereof of treatments intended to prevent or delay the onset of maladaptive correlates of aging in human beings. This journal is indexed on PubMed Central, MedLine,

CAS, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/clinical-interventions-in-aging-journal

